

THE NEW 2021 CANADIAN LIPID GUIDELINES

What should you know about vascular risk reduction?

FRENCH - FRIDAY, APRIL 23RD, 2021

8:00 - 11:00 EDT

ENGLISH - SATURDAY, APRIL 24TH, 2021


11:00 - 14:00 EDT



Mohammed Al-Omran,
MD, MSc, FRCSC
CO-CHAIR
St Michael's Hospital,
University of Toronto,
Toronto, ON



George Thanassoulis,
MD, MSc, FRCPC
CO-CHAIR
McGill University Health Centre,
McGill University, Montréal, QC



Jean C Grégoire,
MD, FRCPC
CO-CHAIR
Institut de Cardiologie de
Montréal, Université de Montréal,
Montréal, QC



Mohammed Al-Omran,
MD, MSc, FRCSC
CO-CHAIR
St Michael's Hospital,
University of Toronto,
Toronto, ON




Lawrence A Leiter,
MD, FRCPC, FACP, FACE,
FAHA, FACC
CO-CHAIR
St Michael's Hospital,
University of Toronto,
Toronto, ON



Glen J Pearson,
BSc, BScPhM, PharmD,
FCSHP, FCCS
CO-CHAIR
University of Alberta,
Edmonton, AB


AGENDA



Sophie Bernard,
M.D., Ph. D., FRCPC
Institut de recherche de
Montréal, Université de
Montréal, Montréal (QC)



Bruno Bernucci,
B.Sc., M.D., CPFC
Polyclinique Levasseur,
Montréal (QC)



Natalie Dayan,
M.D., M. Sc., FRCPC
Institut de recherche du
Centre universitaire de santé
McGill, Université McGill,
Montréal (QC)




Paul Poirier,
M.D., Ph. D., FRCPC
Institut Universitaire de
Cardiologie et de
Pneumologie de Québec,
Université Laval, Québec (QC)



Jean-Claude Tardif,
CM, M.D., FRCPC,
Centre de recherche de
l'Institut de cardiologie
de Montréal, Centre de
coordination des essais
cliniques de Montréal,
Université de Montréal,
Montréal (QC)


FRENCH SESSION			ENGLISH SESSION		
D ^r George Thanassoulis	8:00 EDT	Opening Remarks	11:00 EDT	Dr Lawrence Leiter	
D ^r Paul Poirier	8:10 EDT	What are the LDL-C thresholds for treatment intensification in 2021?	11:10 EDT	Dr Glen Pearson	
D ^r Jean Grégoire	8:30 EDT	How should we intensify lipid-lowering therapy in 2021?	11:30 EDT	Dr Lawrence Leiter	
D ^r George Thanassoulis	8:50 EDT	What are the roles of Lp(a), apoB and triglycerides in risk assessment?	11:50 EDT	Dr Robert Hegele	
D ^r Jean-Claude Tardif	9:10 EDT	Where do the guidelines stand on prescription and non-prescription omega-3 fatty acids?	12:10 EDT	Dr Subodh Verma	
	9:30 EDT	Q&A	12:30 EDT		
D ^{re} Sophie Bernard	9:50 EDT	What is the CAC score, and when and why should it be considered?	12:50 EDT	Dr Vineeta Ahooja	
D ^{re} Natalie Dayan	10:05 EDT	An update on hypertensive disorders of pregnancy and CV risk	13:05 EDT	Dr Priya Manjoo	
D ^r Bruno Bernucci	10:20 EDT	Case-based discussion	13:20 EDT	Dr Richard Ward	
All Faculty	10:40 EDT	Q & A	13:40 EDT	All Faculty	
D ^r Jean Grégoire	11:00 EDT	Closing Remarks	14:00 EDT	Dr Glen Pearson	




Vineeta Ahooja,
M.D., FACC, FASE
The Heart Health Institute,
Scarborough (ON)




Robert A Hegele,
MD, FRCPC
Robarts Research Institute,
Western University,
London ON



Priya S Manjoo,
MD, MSc, FRCPC
Victoria Lipid Clinic,
University of British Columbia,
Victoria, BC



Subodh Verma,
MD, PhD, FRCSC
St Michael's Hospital,
University of Toronto,
Toronto, ON



Richard Ward,
MD, CCFP, FCFP
University of Calgary,
Alberta Health Services,
Calgary Zone
Calgary, AB

LEARNING OBJECTIVES

1. To review the updated 2021 Canadian Cardiovascular Society Guidelines on risk assessment and lipid management.
2. To discuss the Guideline updates for vascular risk assessment.
3. To evaluate therapeutic targets and agents to achieve lipid targets for atherosclerosis according to the new 2021 Canadian Guidelines.

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada. This activity has been approved by the Canadian Society for Vascular Surgery.

For April 23rd, 2021, please register at:
www.CCSLipidFR.com

For April 24th, 2021, please Register at:
www.CCSLipidEN.com

For more information about this program please contact S&L Solutions at
647-462-1138 or info@slsolutionsevents.ca